Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission

PURPOSE: To evaluate whether autologous cytokine-induced killer (CIK) cell immunotherapy improves the prognosis of patients with high-risk diffuse large B cell lymphoma (DLBCL) after the first complete remission (CR). PATIENTS AND METHODS: Peripheral blood mononuclear cells (PBMCs) were extracted fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Min, Wang, Jing, Li, Cui-Ping, Xu, Jing-Yan, Chen, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319512/
https://www.ncbi.nlm.nih.gov/pubmed/32606798
http://dx.doi.org/10.2147/OTT.S254291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319512/
https://www.ncbi.nlm.nih.gov/pubmed/32606798
http://dx.doi.org/10.2147/OTT.S254291

Ejemplares similares